12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

S/GSK1349572: Phase III started

Shionogi and ViiV Healthcare began the double-blind, international Phase III SINGLE trial (ING114467) to compare once-daily 50 mg oral S/GSK1349572 plus Epzicom abacavir/lamivudine vs. once-daily Atripla efavirenz/tenofovir/emtricitabine plus Epzicom over 96 weeks...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >